Loxiglumide is primarily used in medical research and clinical settings as a cholecystokinin (CCK) receptor antagonist. It is particularly valuable in studying the role of CCK in gastrointestinal functions, such as gastric emptying, pancreatic secretion, and gallbladder contraction. In clinical applications, Loxiglumide has been explored for its potential to manage conditions like pancreatitis, where inhibiting CCK can help reduce pancreatic secretion and alleviate symptoms. Additionally, it has been investigated for its effects on appetite regulation and satiety, offering insights into potential treatments for obesity and eating disorders. Its ability to modulate CCK activity also makes it a useful tool in understanding and treating certain gastrointestinal motility disorders.